Program Information

Presented for attendees of The American Transplant Congress™

1:30 PM – 2:30 PM ET
Live Webinar

This virtual CME/MOC event will bring you face-to-face with Drs. Kotton, Pereira, and Silveira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients and answer your questions. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies.

You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals. Do not miss this engaging and impactful educational activity!

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA
Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY
Fernanda P. Silveira, MD, MS, FIDSA
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

1:30 PM – 1:35 PM

Camille Nelson Kotton, MD, FIDSA, FAST
1:35 PM – 1:55 PM

Fernanda P. Silveira, MD, MS, FIDSA
1:55 PM – 2:10 PM

Marcus Pereira, MD, MPH, FAST
2:10 PM – 2:20 PM

All Faculty
2:20 PM – 2:30 PM

All Faculty

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

After this symposium, you should be better able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Joint Acceditation Statement
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-001-L01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationship for all persons in control of content before the learner engages in the education.

This activity is provided by RMEI Medical Education, LLC.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

If you have questions about this CE activity, please contact RMEI Medical Education, LLC.

There is no fee for this educational activity.

Only registrants for ATC will be able to access this educational activity.

Facebook  Twitter  LinkedIn

Additional educational activities offered by RMEI Medical Education, LLC can be found
at or by calling toll-free (866) 770-RMEI.